Phase 2 Trial of Tau Antibody RO7105705 Recruiting Patients with Moderate Alzheimer’s

Phase 2 Trial of Tau Antibody RO7105705 Recruiting Patients with Moderate Alzheimer’s
A Phase 2 trial is enrolling patients with moderate Alzheimer’s to test an investigational antibody known as RO7105705 that targets the Tau protein. The Genentech-sponsored multicenter, randomized study (NCT03828747) intends to assess the efficacy, safety, and pharmacological profile of RO7105705. The company plans to recruit 260 patients in the U.S. More information on study locations and contacts can be found here. After a screening period, patients will receive RO7105705 or placebo by intravenous infusion every two weeks for the first three doses and every four weeks thereafter in a double-blind treatment period. Participants can then undergo an optional open-label extension period which will consist of RO7105705 infusions every four weeks. The last stage will be a safety follow-up period. The trial's primary goal is measuring the change in cognitive function and functional abilities from baseline to week 49. RO7105705, or MTAU9937A, is being developed by Genentech — owned by Roche — and AC Immune. The treatment candidate is a humanized monoclonal antibody, designed to stop the cell-to-cell spread of toxic forms of the Tau protein in the brain. This spread is associated with the onset and progression of cognitive decline in Alzheimer’s disease. “Slowing the propagation of Tau pat
Subscribe or to access all post and page content.